REGiMMUNE to present at the 2009 American Transplant Congress

Mountain View, CA – May 5, 2009 – REGiMMUNE Corporation today announced that a company abstract has been accepted for presentation at the 2009 American Transplant Congress (ATC, May 30 to June 3, 2009 in Boston, Massachusetts). The poster presentation is titled “Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus.” KRN7000 is a synthetic derivative of alpha-galactosylceramide, a small molecule that potently activates natural killer T (NKT) cells. RGI-2001, a proprietary liposomal formulation of KRN7000, is in late preclinical development and REGiMMUNE plans to file an Investigational New Drug (IND) for the prevention of acute Graft-versus-Host disease (GvHD) associated with bone marrow transplantation later this year.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Science in the Morning

From anti-aging news to reporting from deepest space. One email, daily.